SLC5A2 and heart failure: Additionally, the risk of 3P-MACE, hospitalization for heart failure, and cardiovascular death were all significantly reduced, which demonstrated that SGLT2 inhibitors have wide application prospects in preventing the occurrence and development of cardiac complications in patients with poor kidney function.